

**Three dimensional ultrasound and hysteroscopic  
assessment of the uterine cavity in cases of  
abnormal uterine bleeding**

**THESIS**

Submitted by

**Nahid Salman Harazin**

(M.B,BCH)Saint-Petersburg State Medical Academy 1998

Resident of obstetrics and Gynecology, El Shifa Medical Center,  
Palestine)

For fulfillment of Msc.Degree

**Supervisors**

**Prof. Mostafa Ahmed Shokry**

Professor of Obstetrics and Gynecology

Faculty of Medicine. Cairo University.

**Dr. Nermeen Abou Salem**

Assistant Professor of Obstetrics and Gynecology

Faculty of Medicine. Cairo University.

**Faculty of Medicine.**

**Cairo University.**

**2009**

# Acknowledgment

First and foremost, I feel always indebted to **Allah**, The Most Kind and Most Merciful, for enabling me to attain new knowledge and experience through this work.

I would like to express my deepest respectful thanks, and profound gratitude to **Prof. Mostafa Ahmed Shokry**, Professor of Obstetrics and Gynecology, faculty of Medicine, Cairo University, for giving me the honor and great advantage of working under his supervision. His valuable teaching, continuing education, constant support and encouragement to me extend far beyond the limits of this thesis.

I am also deeply grateful to **Dr. Nermeen Abou Salem**, assistant professor of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, for unlimited kind care and great assistance. Her kind help, supervision, meticulous participation, constant guidance throughout every stage of my study and always encouraging me to better.

I would like to express my deep thanks to **Dr. Samah Aboul Gheit**, Assistant Professor of Obstetric and Gynecology, Cairo University, for her valuable scientific guidance.

My deepest gratitude I extend to my whole **family** who offered me support, advice and motivation.

**Nahid S. El Harazin, 2009**

## ***LIST OF ABBREVIATIONS***

<b><i>2D U/S</i></b>	<i>Two dimensional ultrasound</i>
<b><i>3D U/S</i></b>	<i>Three dimensional ultrasound</i>
<b><i>DNA</i></b>	<i>Deoxyribonucleic acid</i>
<b><i>LH</i></b>	<i>Lutenizing hormone</i>
<b><i>MMPs</i></b>	<i>Matrix metalloproteinases</i>
<b><i>TIMP</i></b>	<i>Tissue inhibitor of matrix metalloproteinases</i>
<b><i>VEGF</i></b>	<i>Vascular endothelial growth factor</i>
<b><i>mRNA</i></b>	<i>Microsomal ribonucleic acid</i>
<b><i>TGF</i></b>	<i>Transformation growth factor</i>
<b><i>GDFs</i></b>	<i>Growth differentiation factors</i>
<b><i>TNF</i></b>	<i>Tumor necrosis factor</i>
<b><i>COX</i></b>	<i>Cyclooxygenase</i>
<b><i>PGE</i></b>	<i>Prostaglandin E</i>
<b><i>WHO</i></b>	<i>World Health Organization</i>
<b><i>F.S.H.</i></b>	<i>Follicle stimulating hormone</i>
<b><i>STRAW</i></b>	<i>Stages of the reproductive aging workshop</i>
<b><i>DUB</i></b>	<i>Dysfunctional uterine bleeding</i>
<b><i>C.B.C.</i></b>	<i>Complete blood count</i>
<b><i>CT</i></b>	<i>Computer tomography</i>
<b><i>MRI</i></b>	<i>Magnetic resonant imaging</i>
<b><i>D&amp;C</i></b>	<i>Dilatation and curettage</i>
<b><i>HPF</i></b>	<i>High power field</i>
<b><i>D.M.</i></b>	<i>Diabetes milletus</i>
<b><i>FIGO</i></b>	<i>International federation of gynecology and obstetrics</i>

<b><i>TVS</i></b>	<i>Transvaginal ultrasound</i>
<b><i>ROI</i></b>	<i>Region of interest</i>
<b><i>RI</i></b>	<i>Resistivity index</i>
<b><i>VFI</i></b>	<i>Vascularization flow index</i>
<b><i>CO<sub>2</sub></i></b>	<i>Carbon dioxide</i>
<b><i>NaCl</i></b>	<i>Sodium chloride</i>
<b><i>Hg</i></b>	<i>Mercurary</i>
<b><i>STEP-w</i></b>	<i>Size,topography,extension of the base,penetration,lateral wall</i>
<b><i>SIS</i></b>	<i>Saline infusion sonohysterography</i>
<b><i>MHz</i></b>	<i>Mega hertz</i>
<b><i>SD</i></b>	<i>Standard deviation</i>
<b><i>VOCAL</i></b>	<i>Virtual organ computer aided analysis</i>
<b><i>VI</i></b>	<i>Vascularization index</i>
<b><i>FI</i></b>	<i>Flow index</i>
<b><i>IUCD</i></b>	<i>Intrauterine contraceptive device</i>
<b><i>HRT</i></b>	<i>Hormone replacement therapy</i>
<b><i>H.S.G</i></b>	<i>Hysterosalpengography</i>

# LIST OF TABLES

<b>Table No</b>	<b>Description</b>	<b>Page No</b>
<b>1</b>	Additional Etiology of Menorrhagia	<b>16</b>
<b>2</b>	Davey classification of AUB	<b>20</b>
<b>3</b>	Differential Diagnosis of Abnormal Uterine Bleeding	<b>31</b>
<b>4</b>	Detection rate of focal lesion	<b>33</b>
<b>5</b>	Sonographic criteria of adenomyosis	<b>36</b>
<b>6</b>	Descriptive Statistics	<b>56</b>
<b>7</b>	Different clinical presentation among the study group	<b>56</b>
<b>8</b>	Associated symptom: Pain	<b>57</b>
<b>9</b>	Bulky uterus by pelvic examination:	<b>57</b>
<b>10</b>	Uterine mass by pelvic examination:	<b>57</b>
<b>11</b>	Localization of the mass by pelvic examination:	<b>57</b>
<b>12</b>	Type of lesion by 3D	<b>58</b>
<b>13</b>	Localization of fibroid by 3D	<b>58</b>
<b>14</b>	Fibroid by 3D	<b>59</b>
<b>15</b>	Localization of polyp by 3D	<b>59</b>
<b>16</b>	Polyp by 3D	<b>60</b>
<b>17</b>	Hyperplasia by 3D	<b>60</b>
<b>18</b>	Adenomyosis by 3D	<b>60</b>

<b>19</b>	Bicornuate uterus by 3D	<b>60</b>
<b>20</b>	Hyperplasia by Hysteroscopy	<b>62</b>
<b>21</b>	Localization of fibroid by Hysteroscopy	<b>62</b>
<b>22</b>	Fibroid by Hysteroscopy	<b>63</b>
<b>23</b>	Localization of POLYPS by Hysteroscopy	<b>63</b>
<b>24</b>	POLYP by Hysteroscopy	<b>64</b>
<b>25</b>	Endometrial color by Hysteroscopy	<b>64</b>
<b>26</b>	Adenomyosis by Hysteroscopy	<b>64</b>
<b>27</b>	Bicornuate uterus by Hysteroscopy	<b>64</b>
<b>28</b>	Data by pathology	<b>65</b>
<b>29</b>	3D Fibroid and Hysteroscopic Fibroid A- Crosstabs , - Symmetric Measures	<b>66</b>
<b>30</b>	3D Polyp and Hysteroscopic Polyp: A- Crosstab, B- Symmetric Measures	<b>67</b>
<b>31</b>	3D Hyperplasia and Hysteroscopic Hyperplasia: A- Crosstab , B- Symmetric Measures	<b>68</b>
<b>32</b>	Hysteroscopic Adenomyosis and 3D Adenomyosis: A- Crosstab , B- Symmetric Measures	<b>69</b>
<b>33</b>	Outcome Results	<b>70</b>

## LIST OF FIGURES

<b>Figure No</b>	<b>Description</b>	<b>Page No</b>
<b>1</b>	Prolifertaiive phase of the endometrium	<b>7</b>
<b>2</b>	Secretory phase of the endometrium	<b>8</b>
<b>3</b>	Menstrual phase of the cycle.	<b>9</b>
<b>4</b>	3D ultrasound of fibroid	<b>34</b>
<b>5</b>	2D ultrasound appearance of adenomyosis	<b>35</b>
<b>6</b>	3D ultrasound of adenomyosis	<b>37</b>
<b>7</b>	3D ultrasound of endometrial hyperplasia	<b>38</b>
<b>8</b>	Normal hysteroscopic appearance of the endometrium	<b>40</b>
<b>9</b>	Cervicalcanal polyp by hysteroscopy	<b>42</b>
<b>10</b>	Intracavitary fibroid by hysteroscopy	<b>43</b>
<b>11</b>	Adenomyosis by hysteroscopy	<b>46</b>
<b>12</b>	Polypoid Endometrial hyperplasia by hysteroscopy	<b>47</b>
<b>13</b>	Different clinical presentation among the study group	<b>56</b>
<b>14</b>	Localization of the mass by pelvic exam.	<b>58</b>
<b>15</b>	Localization of fibroid by pelvic exam.	<b>59</b>
<b>16</b>	Localization of polyp by3D	<b>60</b>
<b>17</b>	Data by 3Dultrasound	<b>61</b>
<b>18</b>	Localization of fibroid by 3D	<b>62</b>
<b>19</b>	Localization of POLYP by 3D	<b>63</b>
<b>20</b>	Data by hysteroscopy	<b>64</b>

<b>21</b>	Data by pathology	<b>65</b>
<b>22</b>	Outcome Results of fibroid	<b>71</b>
<b>23</b>	Outcome Results of polyp	<b>71</b>
<b>24</b>	Outcome Results of hyperplasia	<b>71</b>
<b>25</b>	Over all outcome Results	<b>72</b>



# **List of contents**

	<b>Pages</b>
<b>List of abbreviations.</b>	<b>I</b>
<b>List of tables</b>	<b>III</b>
<b>List of figures</b>	<b>V</b>
<b>INTRODUCTION</b>	<b>1</b>
<b>REVIEW OF LITERATURE</b>	<b>3</b>
<b>CHAPTER I: NORMAL MENSTRUATION</b>	
• <b>Regulation of menstrual cycle</b>	<b>4</b>
• <b>Histology of endometrium</b>	<b>6</b>
• <b>Mechanism of menstruation</b>	<b>10</b>
• <b>Mechanism of hemostasis</b>	<b>11</b>
• <b>Physiology of menstruation</b>	<b>12</b>
<b>CHAPTER II: ABNORMAL UTERINE BLEEDING</b>	
• <b>Introduction</b>	<b>13</b>
• <b>Classification</b>	<b>19</b>
• <b>Etiology</b>	<b>21</b>
• <b>Differential diagnosis</b>	<b>31</b>
<b>CHAPTER III- THREE DIMENSIONAL ULTRASOUND</b>	
• <b>Use in detection of uterine lesions</b>	<b>33</b>
<b>CHAPTER IV- HYSTEROSCOPY</b>	
• <b>Normal hysteroscopic appearance of endometium</b>	<b>40</b>
• <b>Role of hysteroscopy in evaluation of AUB</b>	<b>41</b>
• <b>STEP-W classification</b>	<b>44</b>



PATIENTS AND METHOD	49
RESULTS	56
DISCUSSION	73
CONCLUSION	77
SUMMARY	78
REFERENCES	80
ARABIC SUMMARY	-

## **INTRODUCTION**

Abnormal uterine bleeding is commonly encountered in gynecologic practice, accounting for 15% of office visits and almost 25% of gynecologic practice, 10-30% of menstruating women experience heavy menstrual bleeding (*Lippincott Williams & Wilkins, 2008*).

Apart from the regular and traditional bimanual pelvic examination and digital vaginal and speculum examination, endometrial biopsy via dilatation & curettage procedure has been the first and still remaining the gold standard procedure in the investigation of cases of AUB. The aim is to diagnose the endometrial pathology before starting therapy. (*Mencaglia & Hamou, 2000*).

Transvaginal ultrasound is the imaging technique of choice for first line investigation of endometrial abnormalities as a possible cause of abnormal uterine bleeding (*Leone et al., 2007*).

By 2D u/s the pelvic structure could only be evaluated in two primary plans (sagittal and coronal) with minor tilting of the transducer resulting in oblique plane viewing. 3D u/s offers new viewing windows by allowing for arbitrary plane evaluation through a volume data set acquired from the pelvis using both trans-abdominal and trans-vaginal probes. (*Nelson et al., 1999*).

Current 3D ultrasound technology allows storage of complete volumes, has capacity for routine clinical applications. All objects stored in these volumes can be represented in the multiplanar mode (coronal, transverse, sagittal) as well as in form of surface image the major advantage of multiplanar mode is that it enables simultaneous visualization all three

mutually perpendicular sectional planes on display screen (*Merz E. et al., 2007*).

D&C procedure it self, although highly diagnostic yet it has many limitations including the need for a general anesthesia, being a blind procedure with possible complications, only cures 60% of the endometrial cavity, missing a pathology such as polyps and submucous myoma. (*Mencaglia & Hamou, 2000*)

Other less invasive endometrial sampling techniques were tried as endometrial biopsy, Vabra suction curettage, challenge test, H.S.G. but they are fit for screening than reliable diagnostic tool. (*Mencaglia & Hamou, 2000*)

In 1869, the French physician Pantaleone dared to look inside the uterus of a perimenopausal woman complaining of AUB using a primitive hysteroscope reflective candle light without distention medium. (*Cooper, 2000*).

Hysteroscopy permits direct visualization of cervical canal and uterine cavity. Diagnostic hysteroscopy is both accurate and feasible in diagnosis of intrauterine abnormalities. As diagnostic hysteroscopy is predominantly performed in the outpatient clinic, and therapy in an inpatient setting, an accurate diagnosis is important to direct treatment at the specific pathology and avoid needless surgery. Moreover, it may contribute to prognosis of expected quality of life (*Van Dangen H et al., 2007*).

Since the incidence of focal lesions in patients with abnormal uterine bleeding is high, it seems that the most beneficial approach is to proceed with hysteroscopy complemented by endometrial biopsy. (*Shushan A and Revel A, 2002*).

## REVIEW OF LITERATURE

Reproductive capability in young woman begins at the point of menarche, which marks the beginning of an important stage in a young woman's physical reproductive maturation and development (*Butler,1997*).

Understanding of the normal menstrual function is necessary in understanding the etiology of abnormal uterine bleeding. Regular menstrual bleeding occurs as a result of release of F.S.H. by the pituitary which stimulates the ovary to mature an egg, while at the same time estrogen causes the endometrium to thicken . After ovulation , a small cyst on the ovary produces progesterone, if pregnancy doesn't occur progesterone is no longer produced and menses begins(*Forret et al.,2007*).

A normal menstrual cycle is considered to occur every 28 days  $\pm 7$  days . The duration of flow is between 2-7 days , with volume loss of less than 80 ml . (*Forret et al.,2007*)

Menstruation is the physiologic shedding of the endometrium associated with uterine bleeding that occurs at monthly intervals from menarche to menopause. In the years between these two physiologic landmarks, menstruation will occur 400- 500 times in the average female (*Butler,1997*).

The normal human menstrual cycle can be divided into segments: the ovarian and the uterine cycle, based on the organ under examination. the ovarian cycle may be further divided into follicular and luteal phase. Whereas the uterine cycle is divided into corresponding proliferative and secretory phases (*Palter and Olive,1996*).

## **NORMAL MENSTRUATION**

### **Regulation of menstrual cycle:**

The menstrual cycle is regulated by the pituitary-hypothalamic axis. Pulsatile production of GnRH from the hypothalamus causes secretion of FSH and LH from the pituitary. Under the influence of FSH, several ovarian follicles begin to develop. The ovary subsequently produces more estrogen with this stimulation, which functions as negative feedback on FSH, allowing all but one or two dominant follicles to persist (*Seeger BE, 2006*).

During this phase, estradiol feedback on the pituitary causes increase in LH secretion, which causes a small amount of progesterone production, stimulating an LH surge 34 to 36 hours before follicle rupture and ovulation. Once this occurs, the ovarian granulosa cells produce progesterone for about 14 days but involute thereafter unless pregnancy is established. Estrogen acts to increase the thickness and vascularity of the endometrial lining; progesterone increases its glandular secretion and vessel tortuosity. Withdrawal of sex steroids by involution of the corpus luteum results in endometrial sloughing and menstrual bleeding. The follicular phase (first half of the cycle) is variable in length. The luteal phase (from the time of ovulation to menses) is fairly constant at 14 days. (*Smith RP 2002, Bayer SR. 1993*).

### **Phases of ovarian cycle:**

**Follicular phase:** The hormonal feedback promotes the orderly development of a single dominant follicle, which should be mature at mid